Compare LQDT & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDT | KALV |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.6M | 551.2M |
| IPO Year | 2006 | N/A |
| Metric | LQDT | KALV |
|---|---|---|
| Price | $31.83 | $17.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $38.50 | $26.43 |
| AVG Volume (30 Days) | 220.1K | ★ 1.6M |
| Earning Date | 11-20-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.09 | N/A |
| EPS | ★ 0.87 | N/A |
| Revenue | ★ $476,669,000.00 | $1,426,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $204.16 |
| P/E Ratio | $36.57 | ★ N/A |
| Revenue Growth | ★ 31.20 | N/A |
| 52 Week Low | $21.67 | $7.30 |
| 52 Week High | $39.72 | $17.28 |
| Indicator | LQDT | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 76.10 | 70.46 |
| Support Level | $29.72 | $15.88 |
| Resistance Level | $31.96 | $17.10 |
| Average True Range (ATR) | 0.78 | 1.08 |
| MACD | 0.24 | 0.22 |
| Stochastic Oscillator | 97.71 | 96.52 |
Liquidity Services Inc is an online auction marketplace. It manages and sells inventory and equipment for business and government clients by operating a network of e-commerce marketplaces that enable buyers and sellers to transact in an efficient, automated environment offering across different product categories. The company has four reportable segments: GovDeals, Capital Assets Group (CAG), Retail Supply Chain Group (RSCG), and Machinio. It generates majority of its revenue from Retail Supply Chain Group (RSCG) segment which consists of marketplaces that enable corporations located in the United States and Canada to sell excess, returned, and overstocked consumer goods. Geographically, a substantial portion the company's revenue is generated from its business in United States.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.